Najmul Hasan Forhad: VWF Concentrates in Modern Hematology and Transfusion Medicine
Najmul Hasan Forhad, Medical Laboratory Technician at Doctors Without Borders, shared on LinkedIn:
”Topic : Immunohematology and Hemostasis
von Willebrand factor (vWF) concentrates is essential in both clinical practice and laboratory medicine, especially when managing patients with von Willebrand disease (vWD) and certain cases of hemophilia A.
Several therapeutic products are commonly used in replacement therapy, including Alphanate, Humate P, Wilate, and recombinant von Willebrand factor preparations.
Alphanate and Humate P are plasma-derived concentrates containing both vWF and factor VIII, providing effective hemostatic support in patients with bleeding disorders.
Humate P is particularly recognized for its predictable vWF:FVIII ratio and is widely used in surgical prophylaxis and severe bleeding management.
Wilate is another plasma-derived product that is highly purified and formulated to closely resemble the physiologic balance between vWF and factor VIII.
It is commonly used for both acute treatment and prophylactic therapy.
Recombinant von Willebrand factor products represent an important advancement in transfusion medicine and hematology.
Because they are not plasma-derived, they minimize the risk of blood-borne pathogen transmission and offer a more targeted therapeutic approach.
From an educational and examination perspective, understanding the differences between plasma-derived and recombinant products, their clinical indications, and their role in different subtypes of vWD remains highly important for laboratory professionals and healthcare practitioners.
Clinical laboratory science continues to play a critical role in bridging diagnostic hematology with evidence-based patient management.”
Stay updated with Hemostasis Today.
-
Jun 9, 2026, 10:52Vaidehi Prasanth: The Role of Viscoelastic Testing in Low- and Middle-Income Countries
-
Jun 9, 2026, 10:37Maria Bruzelius: Hemophilia and Bleeding Disorder in Clinical Practice at NordCoag 2026
-
Jun 9, 2026, 10:02Understanding Factor X Deficiency – ICHCC
-
Jun 9, 2026, 09:49Lee Severin: Why Patients Love Platelet-Rich Plasma
-
Jun 9, 2026, 09:42Lorena Gerlach: Blood Transportation Duty on this Muggy Spring Day
-
Jun 9, 2026, 08:54Shujha Abbas: Understanding the Real Cost of Gene Therapie
-
Jun 9, 2026, 04:47Akshat Jain: Marstacimab Gets FDA Expension for Children with Hemophilia B
-
Jun 9, 2026, 03:30Fayad Al-Haimus: High-Risk Emergencies and Lifelong Learning at CAEP 2026
-
Jun 9, 2026, 03:14Rucha Patil: A Collaborative Initiative to Transform Rare Blood Disorder Care in Rajasthan